Company intelligence / Profile preview

Sardocor

Lexington, Massachusetts, United Statessardocor.com ↗

Ownership: Private
Development stage: Other

Overview

Sardocor has three ongoing FDA-approved AAV-based gene therapy clinical trials targeting HFrEF, HFpEF, and DMD-CM. SRD‑001 has received Fast Track designation from the FDA for HFpEF. The company uses a proprietary intracoronary delivery method to enhance efficacy and safety by reducing required viral titers. Interim data are positive; over a thousand doses of SRD‑001 have been manufactured. Orphan Drug Designation was granted for the DMD program. Preclinical pipeline includes additional gene therapies and small molecules.

Therapeutic areas: Cardiovascular
Modalities: Gene therapy (AAV-based)Small molecules (preclinical pipeline)
Industry: Biotech

Drug pipeline

13 assets

AAV1/SERCA2a

12 more assets in the full pipeline.

Partnerships

Collaboration/licensing arrangements with global pharmaceutical leaders mentioned but not specified by name

Beyond the preview

Go deeper on Sardocor.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sardocor.